Eli Lilly Enters Psychedelic Mental Health Space with $3.8 Billion AtaiBeckley Acquisition

Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.